CD163 and cancer: Enhance macrophage-specific delivery and reduce systemic toxicity in cancer models. Although CD163-targeted nanoparticles have not yet been tested in HBV, the upregulation of CD163 in hepatic macrophages during chronic HBV makes it a promising target for selective macrophage-specific delivery.